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Purpose of review: Glycosylation patterns have the potential to affect the function of antibody, 
antibody half-life and transplacental transfer from mother to fetus. Here we review recent 
advances in our understanding of how glycosylation patterns of antibodies may be altered 
during pregnancy, vaccination and infection.  
Recent findings: During pregnancy, there is preferential transplacental transfer of NK cell-
activating antibodies that are galactosylated and sialylated, against both bacterial and viral 
antigens. Markers of NK cell function are also associated with a higher abundance of 
galactosylation and sialylation in respiratory syncytial virus-specific IgG, compared to total 
IgG, in infants up to seven months of age which may suggest a role for NK cell-activating 
antibodies as important mediators of immunity during early infancy. Differential glycosylation 
patterns have been observed in some respiratory conditions, as increased non-galactosylated 
antibodies have been associated with the development of chronic inflammatory 
bronchopulmonary dysplasia (BPD) in preterm infants. Glycosylation patterns in children 
appear age-dependent, which could modulate the effector function of IgG. The clinical 
relevance of these findings needs to be established. 
Summary: Glycosylation plays a key role in mediating antibody function. Glycosylation 
patterns associated with positive outcomes from infection in mothers and infants could inform 
the design of the next generation of vaccines for use in pregnancy and infancy. 





Glycosylation is the process through which glycans, or polysaccharides, are added to proteins. 
In the case of antibody, or immunoglobulins (IgG), this addition occurs at the fragment 
crystallisable (Fc) region. The Fc region (Figure 1) is the antibody tail that enables the 
interaction of antibody with cell surface Fc receptors, found on many types of immune cells, 
including natural killer (NK) cells, macrophages and neutrophils. Biantennary 2 n-
acetylglucosamine (GlcNAc) and mannose residues make up the core glycan and different 
glycosylation patterns can be determined by the addition of a bisecting GlcNAc, galactoses, 
sialic acids or fucose. Glycosylation patterns of the Fc region are affected by age,1 sex,2 
pregnancy,3 infection and vaccination,4,5 which in turn impacts antibody function, half-life and 
transfer.6,7 IgG is involved in the adaptive immune response against a number of infections, 
and therefore changes in the glycan structure at the Fc region affect an individual’s 
susceptibility to infection and disease severity.8 Pregnancy and the neonatal period both 
represent key immunological periods in the life-course; including maternal immunomodulation 
during pregnancy, maternal and neonatal vaccine administration, and neonatal exposure to new 
pathogens. The aim of this short review is to evaluate recent antibody glycosylation studies in 






Laying the Foundations: Antibody glycosylation in pregnancy and transfer to the fetus 
in utero   
Pregnancy is a period of dynamic immune modulation, with changes observed in both 
circulating and local immune cell subsets across gestation. In the periphery, this includes T 
helper cell cytokine responses, the proportion of asymmetric antibodies and antibody 
glycosylation.3,9 During pregnancy, IgG antibodies are transported across the placenta to the 
fetus, helping to provide protection against diseases in the neonatal period.10 Taking advantage 
of this are several existing and under-development maternal vaccines, aimed at boosting 
protective IgG levels in the infant through administration in pregnancy. Transfer of maternal 
IgG across the placenta is mediated by binding to receptors such as the neonatal Fc receptor, 
FcRn, and may involve other receptors such as Fc fragment of IgG, low affinity IIIa, receptor 
(FCGR3A). As these receptors bind to IgG through the Fc region, glycosylation affects IgG-
receptor affinity. Changes in IgG glycosylation during pregnancy may therefore not only be 
important for maternal responses to infection and vaccination, but could also affect disease 
susceptibility in the infant, either through altering the quality of antibodies produced by 
pregnant women in response to vaccination or by affecting antibody transfer through the 
placenta through modulation of FcR-IgG interactions.  
Systems serology aims to comprehensively survey a diverse array of antibody features and 
functions to identify antibody features required for protection. Jennewein et al. 201911 utilised 
this approach to investigate whether patterns of antibody glycosylation impacted on antibody 
transfer during pregnancy, using paired maternal and cord samples as a proxy of placental 
transfer efficiency. In serum samples from women vaccinated against Bordetella pertussis 
during their pregnancy, they demonstrated preferential transplacental transfer of NK cell-
activating IgG antibodies against pertussis antigens: compared to pertussis-specific maternal 
antibodies, cord antibodies had increased proportions of CD107a+, IFN-γ+ and MIP-1β+ NK 
cells.11 The authors confirmed that this observation also extended to antibodies against 
respiratory syncytial virus, influenza and measles.11  
The authors proposed that the increased transfer of antibodies involved in NK cell activation 
to neonates was due to preferential placental transfer of antibodies with specific functional 
properties from mother to the fetus. They demonstrated a preference for the enhanced transfer 
of galactosylated and sialylated antibodies across bulk and antigen-specific antibody 
populations, and that digalactosylated antibody interacted effectively with neonatal Fc receptor 
FcRn and FCGR3A, and therefore may be selectively captured and transferred.11 The 
preferential transfer of NK cell-activating antibodies suggests that these antibodies are 
important in providing protection to the neonate in the first few weeks of life, and that NK cells 
may play a pivotal early role in the neonatal immune response to infection. This suggests that 
NK cell-activating antibodies might be important in the protection against a variety of diseases, 
and this might be considered when designing vaccines to be used in pregnancy and in infants 
in early life.  
A limitation of this study is that the authors combined maternal and cord blood data from Tdap-
vaccinated and unvaccinated pregnancies, as their evaluation of total and antigen-specific 
antibody profiles found no difference between mothers from Tdap-vaccinated and 
unvaccinated pregnancies. This is surprising, as all other studies unequivocally show that Tdap-
vaccination during pregnancy boosts vaccine-specific antibody levels in both pregnant women 
and their infants.12–20 The results therefore suggest that the systems serology platform utilised 
in this study was not able to detect Tdap vaccine-specific responses in pregnancy, unlike the 
approaches used by previous studies comparing antibody titres between vaccinated and 
unvaccinated groups.  
Maternal HIV infection during pregnancy is associated with neonatal morbidity and impaired 
vaccine responses in the absence of vertical transmission. Martinez et al. 201921 assessed the 
placental transfer of pathogen-specific IgG in two cohorts of HIV-infected women, one from 
Malawi and one from the United States. The authors report wide variability in the transfer of 
antigen-specific IgG and split the subjects into groups based on transfer efficiencies of IgG 
from mother to fetus categorised as: efficient, variable or poor. Assessing the transfer of 
antibody levels to the HIV-glycoprotein antigen gp120 and also to antibodies to common 
pathogens such as tetanus toxoid and pertussis toxin, differences in Fc region glycan profiles 
were demonstrated within the designated transfer groups. For example, in HIV-infected women 
with variable transfer efficiency, poorly transferred gp120-specific IgG had higher frequencies 
of Fc region fucose.21 This is in contrast to tetanus toxoid and pertussis toxin, which had overall 
lower levels of fucose and were efficiently transferred. The authors therefore propose that Fc 
region glycans may modulate the selective transfer of IgG subpopulations. The limitation of 
this study is that the groups used for the statistical analysis were created post-hoc, with arbitrary 
definitions of ‘efficient’ and ‘poor’ transporters making it difficult to interpret the findings and 
their clinical relevance, or apply to other study populations. Most importantly, the impact of 
maternal HIV infection on the transfer efficiency of antigen-specific IgG and the role of Fc 
region glycosylation in transfer efficiencies remains to be determined, as this study did not 
include an HIV-negative control group. The specific impact of HIV on glycosylation patterns 
or indeed other co-infections warrants further investigation. In addition, and acknowledged by 
the authors, maternal genetic and environmental differences exist between the cohorts from 
Malawi and the United States, which may be why factors associated with placental IgG transfer 
efficiency did not always correlate between cohorts. Despite these limitations, the authors 
demonstrate that placental transfer of maternal IgG is a selective process, determined by a 
combination of factors including antibody subclass and glycan profiles.  
Recent epidemics of Zika virus (ZIKV) have occurred in French Polynesia and South America. 
ZIKV infection in early pregnancy is associated with severe birth defects, primarily 
microcephaly, and there is an urgent need for a preventive vaccine. Frumence et al. 201922 
inoculated mice with an engineered non-glycosylated Zika virus. They observed that immune 
sera from these mice failed to neutralize strains from epidemics in French Polynesia and Brazil. 
The authors suggest that the changes in glycosylation patterns on the virus impacted the 
accessibility of neutralizing antibody epitopes on mature virus particles, something that will 
have important implications in in the development of effective vaccines against ZIKV.  
Time zero: antibody glycosylation at birth  
Non-galactosylated glycans have been associated with inflammation-mediated immune 
diseases.6 The amount of antibody transferred to the fetus increases with gestational age and 
therefore pre-term infants may be at higher risk of infection due to the lower levels of total IgG 
they are born with.23 Twisselmann and colleagues evaluated glycosylation patterns in infants 
grouped by gestation of birth: extremely preterm (born < 28 weeks of gestation), preterm 
infants (born ≥28 and ≤ 35 weeks of gestation) and term infants (>36 weeks).24 They observed 
that the proportion of sialylated IgG Fc glycans was reduced in the extremely low gestational 
age group, compared to preterm and term infants. This effect was also observed for bisecting 
glycans, when comparing infants from the two preterm groups. An increased proportion of 
non-galactosylated glycans were found in the extremely low gestational age infants, compared 
to preterm and term infants.24 The authors then assessed whether there were correlations 
between IgG Fc glycosylation and the clinical characteristics of the preterm infants in the study. 
Whilst there was no significant relationship between Fc glycosylation patterns and sepsis, an 
increase in non-galactosylation was associated with the development of chronic inflammatory 
bronchopulmonary dysplasia (BPD) in preterm infant’s ≥28 week’s gestation.24 Conversely, 
galactosylation was associated with reduced BPD in this group. These effect were not observed 
in pre-term infants born <28 weeks of gestation. Whilst the BPD group in this study was small, 
these findings do suggest that non-galactosylated glycans with pro-inflammatory effects may 
contribute to inflammatory disease. However, further study is required to determine whether 
the increase in non-galactosylation in preterm infants is a cause or an effect of diseases such as 
BPD.  
Some vaccines, such as Bacillus Calmette–Guérin (BCG), can be given at birth. As well as 
protecting against Mycobacterium tuberculosis, the vaccine has been associated with a 
reduction in all-cause mortality, which has been suggested to be linked through reprogramming 
of the neonatal immune system. The host response to M. tuberculosis plays a major role in the 
determination of the different clinical manifestations of the disease and therefore changes in 
the glycosylation status of antibody may reflect the disease status of the host. Although defence 
against M. tuberculosis is primarily mediated by cellular immune responses, changes in 
antibody glycosylation patterns are observed between M. tuberculosis-infected and naive mice, 
in the presence and absence of  BCG vaccination.4 Naïve mice infected with M. tuberculosis 
have increased glycan fucosylation of IgM, suggesting that infection itself alters glycan 
processing. Interestingly, the elevation in fucosylation in response to M. tuberculosis infection 
was blunted in mice that had received the BCG vaccine.4 Removal of fucose has been 
associated with changes in antibody function, most notably the enhancement of antibody-
dependent cellular cytotoxicity.6 The blunting of the fucose response in BCG-vaccinated mice 
may represent a mechanism by which the vaccine is able to contribute to protective immunity 
and the vaccine’s known heterologous effects. This may have important implications in 
countries in which the BCG vaccine is given at birth, but further study is required to determine 
if these findings can be replicated in humans.  
 
Growing with glycans: antibody glycosylation in infancy  
Differential glycosylation patterns have been observed in a study of infant respiratory syncytial 
virus (RSV).25 Blood samples from a cohort of infants less than 7 months of age had higher 
abundance of galactosylation and sialylation in RSV-specific IgG, compared to total IgG. Age-
dependent differences were also noted, with increased fucosylation of both RSV-specific and 
total IgG with age, but decreases in galactosylation, sialylation, and bisecting glycans.25 These 
findings demonstrate age-dependent changes in Fc glycans on both total and antigen-specific 
antibodies, suggesting pan-IgG regulation of glycosylation with age. 
This study also found correlations between RSV-specific IgG Fc glycosylation and markers of 
NK cell function. Although in some cases the correlation was small, the expression of IFN-γ 
and CD107a on NK cells was negatively associated with fucosylation, but positively associated 
with sialylation and galactosylation. Like the study of antibody transfer from mother to fetus 
by Jennewein et al. 201911, a link between glycosylation and NK cell function was 
demonstrated. Importantly, these effects were confirmed to be present in infants in later life, 
suggesting NK cell-activating antibodies are important mediators of immunity during the 
neonatal period.  
Age-dependent differences in glycosylation patterns have been previously demonstrated.1,6 In 
a cross sectional study, de Haan and colleagues found increased fucosylation in early childhood 
(0.1-3.9 years), compared with infants at birth. In contrast, galactosylation, sialylation and 
bisection decreased with age.26 Cheng et al. 201927 also found that age-dependent glycosylation 
patterns were evident across different subclasses of IgG. In this study, children were 
categorised by age: 9 months to 2 years, 2 to 5 years and 5 to 18 years. Whereas the levels of 
monogalactosylated and bisected IgG increased with age, there were decreases in levels of 
digalactosylation, sialylation and fucosylation in older children.27 This suggests that 
glycosylation patterns are age-dependent, which could modulate the effector function of IgG 
in older children.   
Cheng et al. 201927 also hypothesised that changes in patterns of IgG Fc glycosylation may be 
a contributing factor to unexplained recurrent respiratory infections (RRI). Interestingly, the 
levels of bisected glycans were elevated in the RRI group, compared to age-matched healthy 
children, and this was consistent across all subclasses. In addition, sialylation was increased on 
the IgG2/3 and IgG4 subclasses.27 However, much like the study of Twisselmann et al. 201924, 
the question remains whether the differences in glycosylation patterns are a cause or an effect 
of infection.  
As IgG glycan structures can influence effector functions, their role in predicting disease 
susceptibility or severity is becoming increasingly important. In a study of paediatric 
meningococcal sepsis, de Haan et al. 20188 investigated the hypothesis that IgG Fc 
glycosylation might be related to the susceptibility and severity of meningococcal sepsis. 
Addressing the question of susceptibility, the authors observed that Fc fucosylation of IgG1 
was decreased in meningococcal sepsis patients, compared to a cohort of age-matched healthy 
controls. Interestingly, when splitting the cohorts by age (0 to 3.9 years versus 4 to 18 years), 
this effect was more pronounced in patients less than 4 years of age.8 In a reversal of the pattern 
seen for fucosylation, IgG1 Fc bisection was elevated in meningococcal sepsis patients, 
compared to the healthy group. Future studies of this type could assess whether these 
glycosylation patterns are similar to those of healthy children, following recovery from 
meningococcal sepsis, an important question to distinguish between cause and effect. 
Assessing how glycosylation might be related to the severity of meningococcal sepsis, de Haan 
and colleagues observed lower levels of IgG1 hybrid type glycans and IgG2/3 sialylation per 
galactose in infants that later required amputation or died, compared to those that did not.8 This 
could be because severe meningococcal infection induces a change in IgG glycosylation, or 
that infected children who produce these type of IgGs are at higher risk of developing severe 
disease. Access to both convalescent and pre-infection samples would help to address this 
question. The potential to use changes in glycosylation as a biomarker for identifying children 
susceptible to infection is attractive, and future research should focus on whether these 
differences are present on meningococcus-specific IgG compared to total IgG.  
Conclusions 
Glycosylation plays a key role in mediating antibody function, half-life and transfer. It still 
remains to be established how much antibody glycosylation contributes to clinically relevant 
differences in functionality with regards to disease outcomes or vaccine responses in pregnancy 
and the neonatal period. If such clinical relevance can be demonstrated, the assessment of 
glycan patterns could be used as biomarkers to predict immune responses to infection in 
neonates and/or maximise vaccine-induced responses. The studies highlighted and discussed 
in this review suggest that a move towards this type of measurement may help to identify 
individuals that are more susceptible to infection or to their severe outcomes. In the field of 
precision medicine, such results could inform the clinical management of patients, and glycan 
profiling represents an exciting avenue to pursue this. In addition, the discovery of 
glycosylation patterns associated with positive outcomes from infection in mothers and infants 
could inform the design of the next generation of maternal and paediatric vaccines. The impact 
of factors such as age, gender and geographical location on healthy individuals must also be 
considered to further understand the baseline of antibody functionality mediated by 
glycosylation, and to be able to interpret infection- and vaccine-induced responses in this 
context.   
Increasingly, therapeutic antibodies are being designed for use in oncology, autoimmune and 
inflammatory-mediated diseases. There is also potential for their use to improve the health of 
mothers and infants. For example, glycosylation patterns influence the half-life of antibodies, 
and the extension of the half-life of antibody generated through maternal vaccination may 
provide longer-term protection to neonates. In addition, the strength of binding of antibody to 
placental FcRn may be improved by designing antibodies with alternative glycosylation 
patterns, improving the transfer of antibody from mother to fetus.  
Key points 
 Glycosylation patterns determine the type of antibody that is preferentially transferred 
from mothers to the fetus during pregnancy, with a preference for NK cell-activating 
antibodies. 
 The importance of glycosylated NK cell-activating antibodies has also been observed 
in infants infected with RSV 
 Glycosylation patterns in infants are age-dependent and may predict susceptibility or 
severity of disease 
 Glycosylation patterns could inform the design of the next generation of maternal and 
paediatric vaccines, however, whether observed patterns are a cause or effect of 
infection remains to be established 
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Figure 1. Glycosylation of antibodies. A) Glycosylation occurs at the Fc region of IgG B) 
Biantennary GlcNAc (2 n-acetylglucosamine; squares) and mannose residues (circles) make 
up the core glycan. Antibody effector function can be determined by the addition of a bisecting 
GlcNAc, galactoses (circle with cross), sialic acids (diamond) or fucose (triangle). 
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